Luxeptinib

Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells[1][2][3][4].

Product Specifications

CAS Number

[1616428-23-9]

Product Name Alternative

CG-806

UNSPSC

12352005

Target

Apoptosis; Btk; FLT3

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/luxeptinib.html

Purity

98.95

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(NC1=C(F)C=C(F)C=C1F)NC2=CC(F)=C(C(C=CC(C3=NC(C)=CN3)=C45)=C5CNC4=O)C=C2

Molecular Formula

C25H17F4N5O2

Molecular Weight

495.43

References & Citations

[1]Ekaterina Kim MS, et al. CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells. bloodjournal Blood blood (2019) . 134 (Supplement_1) : 3051.|[2]Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes|[3]Guopan Yu, et al.CG '806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutation Status. Blood blood (2017) .130 (Suppl_1) : 462|[4]Aptose Biosciences to Present CG’806 Data at AACR Hematologic Malignancies Meeting